stockrowHalozyme Therapeutics, Inc.
HALO Healthcare Biotechnology
Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024.
- Revenue
- +39.2%
- EPS
- +45.6%
- Free cash flow
- −58.6%
- Total debt
- +115.1%
Quarter to September 2026, against a year earlier
Follow HALO
Alert me
Halozyme Therapeutics, Inc. (HALO) Return on equity
Halozyme Therapeutics, Inc.'s return on equity over the twelve months to 30 September 2026 was 216.4%, up 62.8 percentage points from fiscal 2025 (153.6%). Over the past ten years it has ranged from −1,959.0% (fiscal 2016) to 231.4% (fiscal 2021); the current reading is higher than 73% of that period. That is above the Biotechnology industry median of −50.1% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 153.6% | (44.83) |
| FY2024 | 198.4% | (23.65) |
| FY2023 | 222.1% | 111.84 |
| FY2022 | 110.2% | (121.21) |
| FY2021 | 231.4% | 125.11 |
| FY2020 | 106.3% | 148.74 |
| FY2019 | −42.4% | (7.27) |
| FY2018 | −35.1% | (106.74) |
| FY2017 | 71.6% | 2,030.58 |
| FY2016 | −1,959.0% | (1,882.56) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| HALO Halozyme Therapeutics, Inc. | 216.4% |
| ASND Ascendis Pharma A/S compare | 118.4% |
| EXEL Exelixis, Inc. compare | 44.3% |
| BBIO BridgeBio Pharma, Inc. compare | 26.2% |
| TECH Bio-Techne Corp compare | 9.03% |
| JAZZ Jazz Pharmaceuticals PLC compare | 5.05% |
| BMRN BioMarin Pharmaceutical Inc. compare | −0.31% |
| KYMR Kymera Therapeutics, Inc. compare | −27.3% |
| SMMT Summit Therapeutics PLC compare | −192.5% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on HALO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement